Search results
Showing 736 to 750 of 1070 results for drug therapy
Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic (secondary), oestrogen-receptor positive breast cancer in postmenopausal women who have not had endocrine therapy before.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Percutaneous cementoplasty for palliative treatment of bony malignancies (HTG117)
Evidence-based recommendations on percutaneous cementoplasty for palliative treatment of bony malignancies. This involves injecting a special cement into the bone in order to stabilise it, reduce pain, or both.
View recommendations for HTG117Show all sections
Sections for HTG117
Evidence-based recommendations on normothermic extracorporeal preservation of hearts for transplant after brainstem death. This technique is used to store a donor heart for longer before being transplanted.
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.
This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (HTG522)
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.
View recommendations for HTG522Show all sections
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.